Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains
The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic had brought disastrous consequences throughout the entire world. While several manufactured vaccines have been approved for emergency use, continuous efforts to generate novel vaccines are needed. In this study, we dev...
Main Authors: | Ki-Back Chu, Hae-Ji Kang, Keon-Woong Yoon, Hae-Ahm Lee, Eun-Kyung Moon, Beom-Ku Han, Fu-Shi Quan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/8/920 |
Similar Items
-
Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization
by: Shilei Ding, et al.
Published: (2020-10-01) -
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
by: Daniel Martínez-Flores, et al.
Published: (2021-07-01) -
Comparison of Four SARS-CoV-2 Neutralization Assays
by: Lydia Riepler, et al.
Published: (2021-12-01) -
A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay
by: Gaetano Donofrio, et al.
Published: (2021-04-01) -
Passive Immunity and Antibody Response Induced by <i>Toxoplasma gondii</i> VLP Immunization
by: Hae-Ji Kang, et al.
Published: (2021-04-01)